Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | NMBR | P28336 | 3/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | BRS3 | P32247 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108781 | 1.00 | OPRM1 (0.52) | OPRM1GHSRALOX15CTSLOPRD1 | |
| SCHEMBL26605057 | 0.87 | CTSL (0.54) | OPRM1ALOX15CTSLOPRD1NMBR | |
| SCHEMBL5178667 | 0.87 | CTSL (0.54) | OPRM1ALOX15CTSLOPRD1NMBR | |
| SCHEMBL12464196 | 0.87 | OPRM1 (0.60) | OPRM1ALOX15CTSLOPRD1NMBR | |
| SCHEMBL23266831 | 0.86 | GHSR (0.56) | OPRM1GHSRALOX15CTSLNMBR | |
| SCHEMBL24114750 | 0.85 | MMP2 (0.57) | OPRM1OPRD1NMBRTACR1BRS3 | |
| SCHEMBL29565336 | 0.81 | GHSR (0.58) | OPRM1GHSROPRD1BRS3 | |
| SCHEMBL30464831 | 0.80 | OPRM1 (0.64) | OPRM1OPRD1BRS3 | |
| SCHEMBL18541554 | 0.79 | OPRD1 (0.56) | OPRM1ALOX15CTSLOPRD1ACE | |
| SCHEMBL19791166 | 0.79 | PRMT1 (0.54) | ALOX15OPRD1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8052961-B2 | Highly fluorinated β-amino acids and methods of making and using same | UNIVERSITY OF UTAH FOUNDATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090259020-A1 | HIGHLY FLUORINATED BETA-AMINO ACIDS AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2008034093-A2 | HIGHLY FLUORINATED β-AMINO ACIDS AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259020-A1 | HIGHLY FLUORINATED BETA-AMINO ACIDS AND METHODS OF MAKING AND USING SAME | DAO, ARRB1, ADRA2B | OPRM1 1053/4885GHSR 3677/4885ALOX15 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.